PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2250 participants.
Also called NCT04889872
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 2,250 participants
- Sponsor
- Registry
-
NCT04889872
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Canada, Japan, Netherlands, Switzerland
- Registry status
- Recruiting
Technical summary
Registry record NCT04889872. Randomized; no masking; primary purpose treatment. Start 2021-10-12 (actual); primary completion 2029-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
- Acronym
- PROGRESS
- Condition
- Aortic Stenosis, Calcific
- Condition
- Aortic Valve Stenosis
- Intervention (Device)
- SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA
- Lead sponsor
- Edwards Lifesciences
Record details
- Record id
cardio:ct-nct04889872- Content hash
b83d6e5bb1e6a284a6d93aacb00bc5938598800bb4fc21edf1c0ab395bc628b5